Back to Search
Start Over
Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia
- Source :
- British Journal of Haematology. 177:486-491
- Publication Year :
- 2016
- Publisher :
- Wiley, 2016.
- Subjects :
- Treatment outcome
Comorbidity
03 medical and health sciences
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
In patient
Quinazolinones
Leukemia, Prolymphocytic, B-Cell
business.industry
Prolymphocytic leukaemia
Genetic Variation
Hematology
Phenotype
Treatment Outcome
Purines
030220 oncology & carcinogenesis
Cancer research
Rituximab
Tumor Suppressor Protein p53
business
Idelalisib
B-cell prolymphocytic leukaemia
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 00071048
- Volume :
- 177
- Database :
- OpenAIRE
- Journal :
- British Journal of Haematology
- Accession number :
- edsair.doi.dedup.....cf41bbde63fadb6df53c84a3992356ad